Tirzepatide
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
What is Tirzepatide?
The active ingredient in Mounjaro and Zepbound, a dual GLP-1 and GIP agonist with a roughly five-day half-life.
It is the only injectable in the class carrying an FDA-mandated oral contraceptive interaction warning, so raise it with your prescriber.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Tirzepatide comes up on this site
On GLP Watchdog, Tirzepatide comes up in 228 research articles, 642 seller reviews, 114 FDA warning letters and 4 tools. Browse the FDA warning letters.
Research that discusses it
- Compounded Semaglutide and Tirzepatide Are Ending: What to Do Next
- Is Compounded Tirzepatide Safe? What FDA Has Actually Reported
- Tirzepatide vs Dulaglutide: A Real Head-to-Head
- Tirzepatide Long-Term Side Effects: Where the Evidence Stops
- Tirzepatide Week by Week: What the SURMOUNT Trials Recorded
- Tirzepatide With Glycine, B6 or Niacinamide
- All 228 articles are on the research page
Drug pages
Tools that use it
Seller reviews that mention it
Other terms under Drugs and brands
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers